NYSEAMERICAN:INFUInfuSystem Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InfuSystem in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InfuSystem.

InfuSystem is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for InfuSystem.

InfuSystem Holdings Inc (NYSEAMERICAN:INFU) announced its quarterly earnings results on Thursday, May, 14th. The medical instruments supplier reported ($0.02) EPS for the quarter. The medical instruments supplier earned $21.55 million during the quarter. View InfuSystem's earnings history.

1 Wall Street analysts have issued 12-month price objectives for InfuSystem's stock. Their forecasts range from $17.00 to $17.00. On average, they expect InfuSystem's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 60.2% from the stock's current price. View analysts' price targets for InfuSystem.

News headlines about INFU stock have trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. InfuSystem earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about InfuSystem.

InfuSystem saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 159,400 shares, an increase of 33.3% from the May 31st total of 119,600 shares. Based on an average trading volume of 81,600 shares, the short-interest ratio is presently 2.0 days. Approximately 0.9% of the company's shares are short sold. View InfuSystem's Current Options Chain.

Some companies that are related to InfuSystem include Advanced Medical Solutions Group (AMS), Clover (CLV), Bovie Medical (BVX), CRH Medical (CRH), Tristel (TSTL), Retractable Technologies (RVP), CRH Medical (CRHM), CRH Medical (CRHM), SDI (SDI), Milestone Scientific (MLSS), Omega Diagnostics Group (ODX), Daxor (DXR), Daxor (DXR), IsoRay (ISR) and IsoRay (ISR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InfuSystem investors own include Macquarie Infrastructure (MIC), Second Sight Medical Products (EYES), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Ampio Pharmaceuticals (AMPE), Otelco (OTEL), Pershing Gold (PGLC), VirnetX (VHC), AgroFresh Solutions (AGFS) and Agenus (AGEN).

InfuSystem trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "INFU."

Shares of INFU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INFU stock can currently be purchased for approximately $10.61.

InfuSystem has a market capitalization of $212.94 million. InfuSystem employs 237 workers across the globe.

The official website for InfuSystem is ir.infusystem.com.

InfuSystem's mailing address is 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States. The medical instruments supplier can be reached via phone at +1-248-2911210.